Deferred registration - ICON Clinical (UK) Limited/Newcastle Upon Tyne Hospitals NHS Foundation Trust Code: BP45361
| ISRCTN | ISRCTN10343007 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN10343007 |
| EU Clinical Trials Register (EudraCT) | 2024-511110-21 |
| Integrated Research Application System (IRAS) | 1013710 |
| Central Portfolio Management System (CPMS) | 72779 |
| Sponsor | F. Hoffman-La Roche AG |
| Funder | F. Hoffman-La Roche AG |
- Submission date
- 01/10/2026
- Registration date
- 05/10/2026
- Last edited
- 06/11/2026
- Recruitment status
- Recruiting
- Overall study status
- Deferred
- Condition category
- Other
Plain English summary of protocol
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.
Contact information
Public, Scientific
Building 1
Grenzacherstrasse 124
Basel Town
CH-4070
Switzerland
| Phone | +1 (0)888 662 6728 |
|---|---|
| global-roche-genentech-trials@gene.com |
Principal investigator
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Freeman Hospital
Freeman Road
High Heaton
Newcastle Upon Tyne
NE7 7DN
United Kingdom
| Phone | +44 (0)191 208 1264 |
|---|---|
| nicola.pavese@newcastle.ac.uk |
Study information
| Primary study design | Interventional |
|---|---|
| Allocation | N/A: single arm study |
| Masking | Open (masking not used) |
| Control | Uncontrolled |
| Assignment | Single |
| Purpose | Phase I trial examining safety, tolerability, pharmacokinetics, and pharmacodynamics |
| Scientific title | Deferred registration - ICON Clinical (UK) Limited/Newcastle Upon Tyne Hospitals NHS Foundation Trust Code: BP45361 |
| Study objectives | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. |
| Ethics approval(s) |
Approved 01/05/2026, Cambridge East Research Ethics Committee (2 Redman Place, Stratford, London, EC20 1JQ, United Kingdom; +44 (0)2071048181; cambridgeeast.rec@hra.nhs.uk), ref: 26/EE/0070 |
| Health condition(s) or problem(s) studied | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. |
| Intervention | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. |
| Intervention type | Drug |
| Phase | Phase I |
| Drug / device / biological / vaccine name(s) | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. |
| Primary outcome measure(s) |
|
| Key secondary outcome measure(s) |
|
| Completion date | 11/05/2027 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Lower age limit | 40 Years |
| Upper age limit | 75 Years |
| Sex | All |
| Target sample size at registration | 30 |
| Key inclusion criteria | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. |
| Key exclusion criteria | The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date. |
| Date of first enrolment | 20/10/2026 |
| Date of final enrolment | 31/03/2027 |
Locations
Countries of recruitment
- United Kingdom
- England
- Austria
- Netherlands
- Sweden
Study participating centres
Freeman Road
High Heaton
Newcastle upon Tyne
NE7 7DN
England
Derriford Road
Plymouth
Devon
PL6 8DH
England
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|
Editorial Notes
06/11/2026: Internal review.
01/10/2026: Study's existence confirmed by the HRA.